Chinese COVID-19 vaccine Sinopharm gets WHO approval for emergency use
While WHO has listed the Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Janssen vaccines for emergency use, the Chinese vaccine got delayed recognition due to data related issues
PTI | May 8, 2021 | Updated 07:55 IST
In a big relief for China, the World Health Organisation (WHO) on Friday finally granted the conditional approval to its Sinopharm Covid-19 vaccine for emergency use, a move that could help Beijing step up its vaccine diplomacy amid the surge in coronavirus vaccines in several countries.
China has approved about five of its vaccines for emergency use and especially using Sinopharm and Sinovac vaccines for both at home and abroad. The Sinopharm vaccine was authorised by 45 countries and jurisdictions for use in adults, with 65 million doses administered, according to official media reports. But many countries hesitated using the vaccine as it has not secured recognition from the W
The World Health Organization (WHO) validated on Friday the BBIBP-CorV COVID-19 vaccine developed by China s Sinopharm for emergency use. This afternoon, WHO gave emergency use listing to Sinopharm Beijing s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, said WHO Director-General Tedros Adhanom Ghebreyesus at a press briefing. This expands the list of vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine, he said.
In an official press release, WHO Assistant-Director General for Access to Health Products Mariangela Simao said that the addition of the Sinopharm vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk.
The World Health Organisation (WHO) on Friday approved the Chinese Sinopharm COVID-19 vaccine for emergency use, paving the way for it to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG). The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk, said Dr Mariangela Simao, WHO Assistant-Director General for Access to Health Products, in a statement. We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution, she added.
WHO clears China vaccine (Image: Twitter/WHO) Beijing : In a major relief for China, WHO has allowed emergency use of Sinopharm Covid-19 vaccine, which is the first Chinese vaccine to get WHO approval.
With this China can step up its vaccine diplomacy in several countries where coronavirus cases are on a surge.
China has approved about five of its Covid-19 vaccines for emergency use and especially using Sinopharm and Sinovac vaccines for both at home and abroad.
China was eagerly awaiting the global health body’s nod for it to aggressively push the vaccine among different countries. This afternoon, WHO gave emergency use listing to Sinopharm Beijing s Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, WHO chief Tedros Adhanom Ghebreyesus told a news conference.
2021-05-08 02:27:02 GMT2021-05-08 10:27:02(Beijing Time) Xinhua English
GENEVA, May 7 (Xinhua) The World Health Organization (WHO) validated on Friday the BBIBP-CorV COVID-19 vaccine developed by China s Sinopharm for emergency use. This afternoon, WHO gave emergency use listing to Sinopharm Beijing s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, said WHO Director-General Dr. Tedros Adhanom Ghebreyesus at a press briefing. This expands the list of vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine, he said.
In an official press release, WHO Assistant-Director General for Access to Health Products Dr. Mariangela Simao said that the addition of the Sinopharm vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk.